CELGENE CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Phase 3

Active, not recruiting

Conditions: Eosinophilic Esophagitis

Interventions: Drug: CC-93538

First Posted Date: 2021-08-05

Last Posted Date: 2024-11-27

Lead Sponsor: Celgene

Target Recruit Count: 259

Registration Number: NCT04991935

Locations: 🇺🇸
Local Institution - 082, Phoenix, Arizona, United States
🇺🇸
Local Institution - 041, Scottsdale, Arizona, United States
🇺🇸
Local Institution - 029, Tucson, Arizona, United States

and more 164 locations

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

Recruiting

Conditions: Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse

First Posted Date: 2021-07-29

Last Posted Date: 2023-11-18

Lead Sponsor: Celgene

Target Recruit Count: 1000

Registration Number: NCT04982471

Locations: 🇺🇸
Local Institution - 113, Canton, Ohio, United States
🇺🇸
Local Institution - 102, Houston, Texas, United States
🇺🇸
Local Institution - 103, The Woodlands, Texas, United States

and more 67 locations

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Other: Placebo
Drug: Phenelzine
Drug: Rasigiline
Drug: Ozanimod

First Posted Date: 2021-07-27

Last Posted Date: 2023-08-31

Lead Sponsor: Celgene

Target Recruit Count: 128

Registration Number: NCT04978298

Locations: 🇺🇸
Local Institution - 001, Anaheim, California, United States

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Daratumumab
Drug: Bortezomib
Drug: Iberdomide

First Posted Date: 2021-07-26

Last Posted Date: 2024-12-04

Lead Sponsor: Celgene

Target Recruit Count: 864

Registration Number: NCT04975997

Locations: 🇺🇸
Ohio Health Corporation, Columbus, Ohio, United States
🇺🇸
MetroHealth Medical Center - Main Campus, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States

and more 279 locations

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-92328

First Posted Date: 2021-07-23

Last Posted Date: 2024-02-15

Lead Sponsor: Celgene

Target Recruit Count: 70

Registration Number: NCT04975399

Locations: 🇪🇸
Local Institution - 302, Pamplona, Navarra, Spain
🇨🇦
Local Institution - 204, Edmonton, Alberta, Canada
🇺🇸
Local Institution - 105, Scottsdale, Arizona, United States

and more 12 locations

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

Completed

Conditions: Myelodysplastic Syndromes
Beta-thalassemia

First Posted Date: 2021-07-22

Last Posted Date: 2024-07-12

Lead Sponsor: Celgene

Target Recruit Count: 187

Registration Number: NCT04973280

Locations: 🇮🇹
Local Institutions, Rome, Italy

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: CC-99677
Other: Placebo

First Posted Date: 2021-07-12

Last Posted Date: 2022-11-04

Lead Sponsor: Celgene

Target Recruit Count: 25

Registration Number: NCT04958291

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States
🇺🇸
Local Institution - 001, Long Beach, California, United States

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Phase 1

Recruiting

Conditions: Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions: Drug: CC-91633

First Posted Date: 2021-07-07

Last Posted Date: 2024-08-19

Lead Sponsor: Celgene

Target Recruit Count: 180

Registration Number: NCT04951778

Locations: 🇺🇸
Local Institution - 110, Chicago, Illinois, United States
🇺🇸
Local Institution - 102, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 26 locations

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

Phase 2

Terminated

Conditions: Spondylitis, Ankylosing

Interventions: Drug: CC-99677
Other: Placebo

First Posted Date: 2021-07-01

Last Posted Date: 2024-05-01

Lead Sponsor: Celgene

Target Recruit Count: 167

Registration Number: NCT04947579

Locations: 🇵🇱
Local Institution - 311, Bialystok, Poland
🇵🇱
Local Institution - 301, Elblag, Poland
🇵🇱
Local Institution - 310, Nowa Sol, Poland

and more 60 locations

Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Phase 1

Completed

Conditions: Renal Insufficiency

Interventions: Drug: Iberdomide

First Posted Date: 2021-06-22

Last Posted Date: 2023-02-15

Lead Sponsor: Celgene

Target Recruit Count: 26

Registration Number: NCT04933747

Locations: 🇺🇸
Local Institution - 002, Knoxville, Tennessee, United States
🇺🇸
Local Institution - 003, San Antonio, Texas, United States
🇺🇸
Local Institution - 001, Orlando, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy